888 related articles for article (PubMed ID: 33932409)
1. Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?
Wilkerson JL; Bilbrey JA; Felix JS; Makriyannis A; McMahon LR
Pharmacol Biochem Behav; 2021 Jul; 206():173192. PubMed ID: 33932409
[TBL] [Abstract][Full Text] [Related]
2. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
[TBL] [Abstract][Full Text] [Related]
3. Why do cannabinoid receptors have more than one endogenous ligand?
Di Marzo V; De Petrocellis L
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3216-28. PubMed ID: 23108541
[TBL] [Abstract][Full Text] [Related]
4. Chemical probes of endocannabinoid metabolism.
Blankman JL; Cravatt BF
Pharmacol Rev; 2013 Apr; 65(2):849-71. PubMed ID: 23512546
[TBL] [Abstract][Full Text] [Related]
5. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
[TBL] [Abstract][Full Text] [Related]
6. The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors.
Chicca A; Marazzi J; Gertsch J
Br J Pharmacol; 2012 Dec; 167(8):1596-608. PubMed ID: 22646533
[TBL] [Abstract][Full Text] [Related]
7. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
Kinsey SG; Long JZ; O'Neal ST; Abdullah RA; Poklis JL; Boger DL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2009 Sep; 330(3):902-10. PubMed ID: 19502530
[TBL] [Abstract][Full Text] [Related]
8. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol.
Spoto B; Fezza F; Parlongo G; Battista N; Sgro' E; Gasperi V; Zoccali C; Maccarrone M
Biochimie; 2006 Dec; 88(12):1889-97. PubMed ID: 16949718
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging.
Pascual AC; Gaveglio VL; Giusto NM; Pasquaré SJ
Exp Gerontol; 2014 Jul; 55():134-42. PubMed ID: 24768821
[TBL] [Abstract][Full Text] [Related]
10. New insights into endocannabinoid degradation and its therapeutic potential.
Bari M; Battista N; Fezza F; Gasperi V; Maccarrone M
Mini Rev Med Chem; 2006 Mar; 6(3):257-68. PubMed ID: 16515464
[TBL] [Abstract][Full Text] [Related]
11. Brain regional cannabinoid CB(1) receptor signalling and alternative enzymatic pathways for 2-arachidonoylglycerol generation in brain sections of diacylglycerol lipase deficient mice.
Aaltonen N; Riera Ribas C; Lehtonen M; Savinainen JR; Laitinen JT
Eur J Pharm Sci; 2014 Jan; 51():87-95. PubMed ID: 24012970
[TBL] [Abstract][Full Text] [Related]
12. Cannabis, cannabinoid receptors, and endocannabinoid system: yesterday, today, and tomorrow.
Wu J
Acta Pharmacol Sin; 2019 Mar; 40(3):297-299. PubMed ID: 30670816
[No Abstract] [Full Text] [Related]
13. The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.
Wilkerson JL; Ghosh S; Mustafa M; Abdullah RA; Niphakis MJ; Cabrera R; Maldonado RL; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Mar; 114():156-167. PubMed ID: 27890602
[TBL] [Abstract][Full Text] [Related]
14. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice.
Booker L; Kinsey SG; Abdullah RA; Blankman JL; Long JZ; Ezzili C; Boger DL; Cravatt BF; Lichtman AH
Br J Pharmacol; 2012 Apr; 165(8):2485-96. PubMed ID: 21506952
[TBL] [Abstract][Full Text] [Related]
15. Dynamic changes to the endocannabinoid system in models of chronic pain.
Rani Sagar D; Burston JJ; Woodhams SG; Chapman V
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3300-11. PubMed ID: 23108548
[TBL] [Abstract][Full Text] [Related]
16. 1-, 2- and 3-AG as substrates of the endocannabinoid enzymes and endogenous ligands of the cannabinoid receptor 1.
Farah SI; Hilston S; Tran N; Zvonok N; Makriyannis A
Biochem Biophys Res Commun; 2022 Feb; 591():31-36. PubMed ID: 34995983
[TBL] [Abstract][Full Text] [Related]
17. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
Desroches J; Charron S; Bouchard JF; Beaulieu P
Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808
[TBL] [Abstract][Full Text] [Related]
18. The endocannabinoid system: Overview of an emerging multi-faceted therapeutic target.
Chanda D; Neumann D; Glatz JFC
Prostaglandins Leukot Essent Fatty Acids; 2019 Jan; 140():51-56. PubMed ID: 30553404
[TBL] [Abstract][Full Text] [Related]
19. Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.
Manterola A; Bernal-Chico A; Cipriani R; Canedo-Antelo M; Moreno-García Á; Martín-Fontecha M; Pérez-Cerdá F; Sánchez-Gómez MV; Ortega-Gutiérrez S; Brown JM; Hsu KL; Cravatt B; Matute C; Mato S
Biochem Pharmacol; 2018 Nov; 157():189-201. PubMed ID: 30075103
[TBL] [Abstract][Full Text] [Related]
20. The endocannabinoid system.
Kilaru A; Chapman KD
Essays Biochem; 2020 Sep; 64(3):485-499. PubMed ID: 32648908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
